Study on Early Lyme Neuroborreliosis
NCT00910533 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2018-10-16
Summary
The purpose of this study is to determine clinical course and the sequelae of early Lyme neuroborreliosis after treatment with ceftriaxone.
Conditions
- Nervous System Lyme Borreliosis
Interventions
- DRUG
-
ceftriaxone 2 g od i.v. for 14 days
Sponsors & Collaborators
-
University Medical Centre Ljubljana
lead OTHER
Principal Investigators
-
Franc Strle, MD · UMC Ljubljana
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 15 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-01-01
- Primary Completion
- 2018-12-31
- Completion
- 2020-12-31
Countries
- Slovenia
Study Locations
More Related Trials
-
Patient's Pretreatment Expectations About Post-Lyme Symptoms
NCT03462329 ·Status: RECRUITING ·Phase: NA
-
A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
NCT00001539 ·Status: RECRUITING
-
Antibiotic Treatment of Multiple Erythema Migrans
NCT01163994 ·Status: UNKNOWN ·Phase: NA
-
Doxycycline in Therapy of Erythema Migrans
NCT01475708 ·Status: COMPLETED
-
Inflammatory Responses in Solitary and Multiple Erythema Migrans
NCT03980015 ·Status: COMPLETED
-
Aseptic Meningoencephalitis in Slovenia
NCT02328469 ·Status: UNKNOWN
-
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease
NCT00001101 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease
NCT00000938 ·Status: COMPLETED ·Phase: PHASE3
-
Clinicaly Manifested Reinfections with Borrelia Burgdorferi Sensu Lato
NCT06835075 ·Status: ACTIVE_NOT_RECRUITING
-
Ceftriaxone for Post-Treatment Lyme Disease
NCT06785402 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Persistent Lyme Empiric Antibiotic Study Europe
NCT01207739 ·Status: COMPLETED ·Phase: PHASE4
-
Tick-borne Encephalitis and Borrelial Antibodies in Serum
NCT03956446 ·Status: RECRUITING ·Phase: NA
-
Comparison of IFA and LIAISON® for Diagnosis of Early Disseminated Lyme Borreliosis in Children, Younger Than 18 Years
NCT03798704 ·Status: COMPLETED
-
Place of Intrathecal CXCL-13 in the Diagnosis of Lyme Neuroborreliosis
NCT05625100 ·Status: UNKNOWN
-
Tick-borne Encephalitis and Positive Borrelial Antibodies
NCT02463942 ·Status: UNKNOWN ·Phase: NA
-
Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome
NCT01518192 ·Status: COMPLETED ·Phase: PHASE4
-
Searching for Persistence of Infection in Lyme Disease
NCT01143558 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Management of Tick-borne Encephalitis
NCT06593249 ·Status: COMPLETED
-
Study of the Clinical, Microbiological and Epidemiological Characteristics of Recurrent Imported Borreliosis Confirmed by the CNR Borrelia
NCT07335965 ·Status: RECRUITING
-
Postencephalitic Symptoms After Tick Borne Encephalitis
NCT00941590 ·Status: UNKNOWN
-
Direct Diagnosis of Disseminated Lyme Borreliosis.
NCT04719962 ·Status: UNKNOWN ·Phase: NA
-
Tick-borne Encephalitis and Possible Borrelial Serology
NCT03958058 ·Status: COMPLETED
-
64Cu-DOTATATE-PET for Lyme Neuroborreliosis
NCT06392815 ·Status: RECRUITING ·Phase: NA
-
Inflammatory Mediators in Erythema Migrans
NCT03956212 ·Status: COMPLETED ·Phase: NA
-
Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease
NCT06611111 ·Status: RECRUITING ·Phase: EARLY_PHASE1